SP 0256
Alternative Names: hMPV mRNA LNP 1; Respiratory syncytial virus mRNA vaccine - Sanofi; RSV mRNA LNP 1; RSV mRNA LNP CL 0059; RSV mRNA LNP CL 0137; RSV mRNA LNP vaccine - Sanofi; RSV/hMPV mRNA LNP 1; RSV/hMPV mRNA LNP 2; RSV/hMPV mRNA Vaccine; SP-0256Latest Information Update: 27 Feb 2024
At a glance
- Originator Sanofi
- Class Respiratory syncytial virus vaccines; RNA vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Respiratory syncytial virus infections
- Phase I Metapneumovirus infections
Most Recent Events
- 23 Jan 2024 Phase-I clinical trials in Metapneumovirus infections (Prevention) in Australia (IM) (NCT06237296)
- 23 Jan 2024 Phase-I clinical trials in Respiratory syncytial virus infections (Prevention) in Australia (IM) (NCT06237296)
- 23 Jan 2024 Sanofi plans a phase I trial for Respiratory syncytial virus infections (Prevention, In adults, In the elderly ) and Metapneumovirus infections (Prevention, In adults, In the elderly) (IM) in February 2024 (NCT06237296)